Cervical Cancer

A test for dangerous strains of high-risk HPV using messenger RNA was shown to be reliable and effective for cervical cancer risk stratification.

Multiple lesion-directed biopsies can drastically improve the sensitivity of colposcopy in women referred for abnormal cervical cancer screening.

More than 11% of all eligible women had not been screened for cervical cancer in the past 5 years, according to a study by researchers at the CDC.

Nurses trained in the visual inspection with acetic acid cervical cancer screening method were able to successfully perform colposcopy and detect cervical lesions.

Vaccines including that for HPV, which helps prevent cervical cancer, show no association at all with multiple sclerosis or other CNS demyelinating syndromes.

Hydronephrosis is associated with substantial morbidity in patients with cervical cancer, and is potentially associated with poorer survival as well.

A new human papillomavirus (HPV) vaccine that protects against nine types of HPV and would protect against about 90% of cervical cancers could be available in 2015.

Adding the TKI cediranib to chemotherapy improved progression-free survival in patients with metastatic or relapsed cervical cancer, according to a study presented at the 2014 ESMO Congress.

The US Food and Drug Administration has approved bevacizumab (Avastin) for the treatment of patients with recurrent or metastatic cervical cancer.

The FDA has approved an HPV DNA test to be used as a primary screening method for cervical cancer in women 25 and older. The test can also give insight into future risk of cervical cancer.

An FDA panel has recommended that a DNA test that screens for HPV in women can replace the standard Pap smear as a first-line primary cervical cancer screening test.

A new study has demonstrated that a therapeutic vaccine against HPV can stimulate an immune response and regression of high-grade cervical dysplasia, a precursor to cervical cancer in women with an HPV infection.

An analysis of four randomized clinical trials from Europe shows that HPV-based screening resulted in a greater long-term protection from invasive cervical cancer compared with a Pap test.

Results from the phase III GOG 240 trial, presented at ASCO, showed the addition of bevacizumab (Avastin) to standard chemotherapy improved overall survival by nearly 4 months in women with advanced or relapsed cervical cancer.

Biennial visual inspection with acetic acid (vinegar) screening by trained public health workers significantly reduced cervical cancer mortality in a large cluster-randomized controlled trial conducted among thousands of women from poor neighborhoods in Mumbai, India.

There has been a decline in overall cancer screening among the US population. Only colorectal cancer screening rates met current screening goals. Cancer survivors specifically met current national screening goals with the exception of cervical cancer screening.

A new study finds that baseline testing for HPV can better predict long-term negative cervical cancer outcomes compared to a Pap smear.

The European Society of Gynaecological Oncology (ESGO) biennial meeting is taking place in Milan, Italy, and will run from September 11-14, 2011.

A study published in Lancet Oncology shows that an AS04-adjuvanted HPV 16 and HPV 18 vaccine developed by GlaxoSmithKline Biologicals can offer protection against anal cancer.

One of the highlights of the released abstracts is “Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice” (J Clin Oncol 29: 2011 (suppl; abstr 1508). The large-scale study showed the effectiveness of human papillomavirus (HPV) testing alone or in combination with cytology testing for identifying women at high-risk for cervical cancer development.

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, with approximately 20 million people currently infected and an additional 6.2 million infected each year, despite increased media attention to HPV as a cause of cervical cancer and the availability of a vaccination to reduce HPV-associated cervical cancer.

Investigators from the German Cancer Research Center in Heidelberg reported on the effects of LMV-601 on cultured human cervical cells. LMV-601 is a phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor.

With the increased use of human papillomavirus vaccines such as Gardasil and Cervarix, the medical community is likely to see a decrease in cases of genital warts and other complications caused by several HPV strains. But it may be a decade or two before oncologists can expect to see a decline in cervical cancer rates attributable to the use of these relatively new vaccines.

Human papilloma virus often lurks in cervical tissue, and it can cause cancer there. But the infection is also often benign, particularly among young women. Biomarkers of transformation are proving useful in helping cytologists to decide when a suspicious-looking Pap result is truly a sign of trouble.

Of the predominant gynecologic cancers, cancer of the uterine cervix is the least common, with only 11,270 new cases anticipated in the United States in 2009. Nevertheless, approximately 4,070 women die of cancer of the uterine cervix annually in the United States.

The American College of Obstetricians and Gynecologists has recommended that women begin cervical cancer screening at age 21 rather than three years after the onset of sexual activity, as was previously recommended by the group.

Out with the old and in with the new is a commonly followed maxim in medicine given the rapid pace of developments in diagnosis and treatment. Human papillomavirus vaccines are relative newcomers to the cervical cancer armamentarium, but they cannot be relied on to do the job on their own; screening is still a must.

Cervarix has won FDA approval for the prevention of cervical pre-cancers and cervical cancer associated with HPV-16 and HPV-18 for use in girls and young women (ages 10-25), according to GlaxoSmithKline.

PET/CT is gaining recognition both medically and politically when it comes to sizing up cancer. And the timing for oncologists couldn’t be better.

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s human papillomavirus bivalent (types 16 and 18) vaccine, recombinant (Cervarix) for the prevention of cervical precancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10–25).